LON:IMM ImmuPharma Interim Earnings Report GBX 4.50 +0.20 (+4.65%) As of 07/17/2026 12:00 PM Eastern ProfileEarnings History ImmuPharma EPS ResultsActual EPS-GBX 0.38Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AImmuPharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AImmuPharma Announcement DetailsQuarterInterimDate8/6/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile ImmuPharma Earnings HeadlinesImmuPharma appoints Bachem to manufacture key ingredient for diabetes drugJune 25, 2026 | uk.finance.yahoo.comImmuPharma flags Murcia research into P140 as potential brain cancer treatmentJune 24, 2026 | uk.finance.yahoo.comSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in 50 years - and it has nothing to do with a single stock. According to multiple Wall Street banks, a coming crisis could keep your portfolio in the red for 10 years or longer. Keith Kaplan, CEO of TradeSmith, is sharing what you can do to protect your wealth before it hits.July 18 at 1:00 AM | TradeSmith (Ad)ImmuPharma focused on securing P140 licensing deal in 2026May 28, 2026 | uk.finance.yahoo.comImmuPharma launches regulatory push for Kapiglucagon diabetes drugMay 6, 2026 | uk.finance.yahoo.comImmuPharma PLCApril 24, 2026 | marketwatch.comSee More ImmuPharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like ImmuPharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on ImmuPharma and other key companies, straight to your email. Email Address About ImmuPharmaImmuPharma (LON:IMM) (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.View ImmuPharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 07/13- 07/17The Market Sold Alcoa After Earnings—But It May Be Missing the Real StoryTSMC Just Gave AI Chip Bulls Another Reason to Stay ConfidentAehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue GrowthWhy Intuitive Surgical’s Strong Quarter Still Spooked InvestorsGE Aerospace Faces a Prove-It Moment in Q2 EarningsWhy Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Upcoming Earnings General Motors (7/21/2026)Northrop Grumman (7/21/2026)America Movil (7/21/2026)Alphabet (7/21/2026)Chubb (7/21/2026)Capital One Financial (7/21/2026)Interactive Brokers Group (7/21/2026)Charles Schwab (7/21/2026)Danaher (7/21/2026)Novartis (7/21/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
